Analogues Market" report has been added to ResearchAndMarkets.com's offering. This report provides detailed information on glucagon-like peptide-1 (GLP-1) analogues. It analyzes market trends for ...

Key market opportunities for GLP-1 analogues include growth in the oral administration segment, expanding presence in ...

GLP-1 analogues are reshaping diabetes and obesity care as innovation in drug delivery, expanding indications, and strong R&D pipelines drive explosive global demand.”Boston, Jan. 30, 2026 (GLOBE ...

The health insurance coverage for the diabetes treatment Ozempic has begun. The eligibility criteria are strict. This is ...

This is the third program that successfully combines Entera’s oral peptide N-Tab® platform with OPKO’s advanced protein chemistry capabilitiesThe ...

GLP-1 receptor agonists show promise beyond obesity but require careful use due to sarcopenia risk and complex effects on mental health.

PF'3944 is an ultra-long-acting fully biased GLP-1 receptor agonist (RA). It is being developed as a single agent weekly and as a monthly therapy, and in combination with various peptides including an ...

Novo Nordisk A/S has disclosed GLP-1 polypeptide analogues acting as glucagon-like peptide-1 receptor (GLP-1R) agonists. As such, they are reported to be useful for the treatment of obesity and ...

While Baseline Therapeutics declined to disclose its starting capital, the startup said it will use the funds to push its GLP ...